BOCA RATON, Fla., June 30, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has enteredinto a multi-product agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), based in Seoul, Korea, under which Breckenridge and SCD expect to develop and commercialize at least seven ANDAs.
This agreement contemplates filing ANDAs for at least six ophthalmic products and one otic product, beginning in the first quarter of 2018. The total addressable IMS market value for this portfolio is $2.4 billion USD.
This selection of products also contributes to Breckenridge's Paragraph IV portfolio. Breckenridge currently has twenty-six (26) ANDAs filed and pending with FDA that contain Paragraph IV patent challenges, and intends to continue that trend in the next several years, focusing on niche and first-to-file Paragraph IV opportunities with certain barriers to entry.
About Breckenridge:Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com
About Sam Chun Dang Pharm. Co. Ltd.:SCD is a privately-held manufacturer based in Seoul, Korea that develops and manufactures ophthalmic solutions, solid orals, nasal solutions, and ampules for a wide range of therapeutic classes. Founded in 1943, SCD exports its products to Asia, the Middle East, North America, and throughout Latin America.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-inc-signs-multi-product-agreement-with-sam-chun-dang-pharm-co-ltd-300481517.html
SOURCE Breckenridge Pharmaceutical, Inc.
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All